deltatrials
Completed PHASE2 INTERVENTIONAL 4-arm NCT05014412

A Study to Learn About the Study Medicine (Elranatamab) in Participants With Multiple Myeloma That Has Come Back After Responding to Treatment or Has Not Responded to Treatment (MagnetisMM-9)

A PHASE 1/2, OPEN-LABEL, MULTICENTER STUDY TO EVALUATE A DOSING REGIMEN WITH TWO STEP-UP PRIMING DOSES AND LONGER DOSING INTERVALS OF ELRANATAMAB (PF-06863135) MONOTHERAPY IN PARTICIPANTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA

Sponsor: Pfizer

Interventions Elranatamab
Updated 28 times since 2021 Last updated: Jan 22, 2026 Started: Oct 7, 2021 Primary completion: Jun 15, 2023 Completion: Dec 12, 2025
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT05014412, this PHASE2 trial focuses on Multiple Myeloma and remains completed. Sponsored by Pfizer, it has been updated 28 times since 2021, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

~Sep 2021 – ~Oct 2021 · 30 days · monthly snapshot~Oct 2021 – ~Nov 2021 · 31 days · monthly snapshot~Nov 2021 – ~Dec 2021 · 30 days · monthly snapshot~Dec 2021 – ~Jan 2022 · 31 days · monthly snapshot~Jan 2022 – ~Feb 2022 · 31 days · monthly snapshot~Feb 2022 – ~Apr 2022 · 59 days · monthly snapshot~Apr 2022 – ~May 2022 · 30 days · monthly snapshot~May 2022 – ~Jun 2022 · 31 days · monthly snapshot~Jun 2022 – ~Jul 2022 · 30 days · monthly snapshot~Jul 2022 – ~Sep 2022 · 2 months · monthly snapshot~Sep 2022 – ~Nov 2022 · 2 months · monthly snapshot~Nov 2022 – ~Dec 2022 · 30 days · monthly snapshot~Dec 2022 – ~Apr 2023 · 4 months · monthly snapshot~Apr 2023 – ~Jul 2023 · 3 months · monthly snapshot~Jul 2023 – ~Oct 2023 · 3 months · monthly snapshot~Oct 2023 – ~Mar 2024 · 5 months · monthly snapshot~Mar 2024 – ~Jul 2024 · 4 months · monthly snapshot~Jul 2024 – ~Aug 2024 · 31 days · monthly snapshot~Aug 2024 – ~Sep 2024 · 31 days · monthly snapshot~Sep 2024 – ~Nov 2024 · 2 months · monthly snapshot~Nov 2024 – ~Dec 2024 · 30 days · monthly snapshot~Dec 2024 – ~Mar 2025 · 3 months · monthly snapshot~Mar 2025 – ~May 2025 · 2 months · monthly snapshot~May 2025 – ~Sep 2025 · 4 months · monthly snapshot~Sep 2025 – ~Oct 2025 · 30 days · monthly snapshot~Oct 2025 – ~Nov 2025 · 31 days · monthly snapshot~Nov 2025 – ~Feb 2026 · 3 months · monthly snapshot~Feb 2026 – present · 7 months · monthly snapshot

Change History

28 versions recorded
  1. Feb 2026 — Present [monthly]

    Completed PHASE2

    Status: Active Not RecruitingCompleted

  2. Nov 2025 — Feb 2026 [monthly]

    Active Not Recruiting PHASE2

  3. Oct 2025 — Nov 2025 [monthly]

    Active Not Recruiting PHASE2

  4. Sep 2025 — Oct 2025 [monthly]

    Active Not Recruiting PHASE2

  5. May 2025 — Sep 2025 [monthly]

    Active Not Recruiting PHASE2

Show 23 earlier versions
  1. Mar 2025 — May 2025 [monthly]

    Active Not Recruiting PHASE2

  2. Dec 2024 — Mar 2025 [monthly]

    Active Not Recruiting PHASE2

  3. Nov 2024 — Dec 2024 [monthly]

    Active Not Recruiting PHASE2

  4. Sep 2024 — Nov 2024 [monthly]

    Active Not Recruiting PHASE2

  5. Aug 2024 — Sep 2024 [monthly]

    Active Not Recruiting PHASE2

  6. Jul 2024 — Aug 2024 [monthly]

    Active Not Recruiting PHASE2

  7. Mar 2024 — Jul 2024 [monthly]

    Active Not Recruiting PHASE2

  8. Oct 2023 — Mar 2024 [monthly]

    Active Not Recruiting PHASE2

    Status: RecruitingActive Not Recruiting

  9. Jul 2023 — Oct 2023 [monthly]

    Recruiting PHASE2

  10. Apr 2023 — Jul 2023 [monthly]

    Recruiting PHASE2

  11. Dec 2022 — Apr 2023 [monthly]

    Recruiting PHASE2

  12. Nov 2022 — Dec 2022 [monthly]

    Recruiting PHASE2

  13. Sep 2022 — Nov 2022 [monthly]

    Recruiting PHASE2

  14. Jul 2022 — Sep 2022 [monthly]

    Recruiting PHASE2

  15. Jun 2022 — Jul 2022 [monthly]

    Recruiting PHASE2

  16. May 2022 — Jun 2022 [monthly]

    Recruiting PHASE2

  17. Apr 2022 — May 2022 [monthly]

    Recruiting PHASE2

  18. Feb 2022 — Apr 2022 [monthly]

    Recruiting PHASE2

  19. Jan 2022 — Feb 2022 [monthly]

    Recruiting PHASE2

  20. Dec 2021 — Jan 2022 [monthly]

    Recruiting PHASE2

  21. Nov 2021 — Dec 2021 [monthly]

    Recruiting PHASE2

    Status: Not Yet RecruitingRecruiting

  22. Oct 2021 — Nov 2021 [monthly]

    Not Yet Recruiting PHASE2

  23. Sep 2021 — Oct 2021 [monthly]

    Not Yet Recruiting PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Pfizer
Data source: Pfizer

For direct contact, visit the study record on ClinicalTrials.gov .